Cancer-associated_cachexia

Efficacy and safety of anamorelin for cancer cachexia in patients with unresectable or recurrent gastric cancer: a multicentre, open-label, randomised controlled trial.

BACKGROUND

Anamorelin, a ghrelin receptor agonist, has shown efficacy in lung cancer cachexia. We conducted the first randomized controlled trial to evaluate its effects in gastric cancer cachexia.

METHODS

In this multicenter, open-label randomized controlled trial conducted across 10 hospitals in Japan, patients...

🗓️ 2025-11-03
📰 Publication: Eclinicalmedicine
Read MoreEfficacy and safety of anamorelin for cancer cachexia in patients with unresectable or recurrent gastric cancer: a multicentre, open-label, randomised controlled trial.

Transcriptional landscape of skeletal muscle in cancer patients.

Bhatt et al. have identified two RNAome-based skeletal muscle subtypes in cancer cachexia. The first subtype is cachexia associated with weight and muscle loss, fiber atrophy, and shortened survival. Furthermore, this subtype has dysregulated post-transcriptional networks involving hub long noncoding...

🗓️ 2025-11-02
📰 Publication: Trends In Molecular Medicine
Read MoreTranscriptional landscape of skeletal muscle in cancer patients.

Pancreatic Damage in Ovarian Cancer-Associated Cachexia Is Driven by Activin A Signalling.

BACKGROUND

Cancer-associated cachexia (CAC) is a severe metabolic disorder characterized by involuntary weight loss, skeletal muscle atrophy and adipose tissue depletion. It is a major contributor to morbidity and mortality in the advanced stages of various cancers. However, the impact of...

🗓️ 2025-10-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MorePancreatic Damage in Ovarian Cancer-Associated Cachexia Is Driven by Activin A Signalling.

New models for cancer cachexia and their application to drug discovery.

Cancer cachexia (CC) is a multifactorial syndrome characterized by progressive weight loss, anorexia, and loss of skeletal muscle and fat mass, resulting in reduced quality of life and poor prognosis. Currently, there are no approved pharmacological treatments for CC, highlighting...

🗓️ 2025-10-03
📰 Publication: Expert Opinion On Drug Discovery
Read MoreNew models for cancer cachexia and their application to drug discovery.

Cachexia progression differs among mouse models of metastatic triple-negative breast cancer.

Cancer-associated cachexia decreases quality of life, reduces therapy response, and diminishes survival prospects. Effective cachexia countermeasures remain a significant unmet need. Research into cancer cachexia has made extensive use of models of colon, lung and pancreatic cancers. However, while cachexia...

🗓️ 2025-10-03
📰 Publication: American Journal Of Physiology-Cell Physiology
Read MoreCachexia progression differs among mouse models of metastatic triple-negative breast cancer.

Vagal blockade of the brain-liver axis deters cancer-associated cachexia.

Cancer-associated cachexia (CAC) is a multifactorial and currently incurable syndrome responsible for nearly one-third of cancer-related deaths. It contributes to therapy resistance and increases mortality among affected patients. In this study, we show that cancer-induced systemic inflammation alters vagal tone...

🗓️ 2025-07-29
📰 Publication: Cell
Read MoreVagal blockade of the brain-liver axis deters cancer-associated cachexia.

Cancer therapy and cachexia.

A central challenge in cancer therapy is the effective delivery of anticancer treatments while minimizing adverse effects on patient health. The potential dual impact of therapy is clearly illustrated in cancer-associated cachexia, a multifactorial syndrome characterized by involuntary weight loss,...

🗓️ 2025-08-01
📰 Publication: Journal Of Clinical Investigation
Read MoreCancer therapy and cachexia.

Olanzapine for Anorexia in Patients With Incurable Cancer and Cachexia (OlAnCa): A Double-Blind, Placebo-Controlled, Randomized Clinical Trial.

Pharmacologic options for managing anorexia in cancer cachexia are limited. This trial aimed to evaluate the efficacy of olanzapine in alleviating anorexia in patients with incurable cancer and cachexia. This double-blind, placebo-controlled, randomized trial included adult patients with incurable cancer...

🗓️ 2025-07-30
📰 Publication: Journal Of The National Comprehensive Cancer Network
Read MoreOlanzapine for Anorexia in Patients With Incurable Cancer and Cachexia (OlAnCa): A Double-Blind, Placebo-Controlled, Randomized Clinical Trial.

Functional liver genomics identifies hepatokines promoting wasting in cancer cachexia.

In cancer cachexia, the presence of a tumor triggers systemic metabolic disruption that leads to involuntary body weight loss and accelerated mortality in affected patients. Here, we conducted transcriptomic and epigenomic profiling of the liver in various weight-stable cancer and...

🗓️ 2025-07-18
📰 Publication: Cell
Read MoreFunctional liver genomics identifies hepatokines promoting wasting in cancer cachexia.

Thymic Microenvironment Remodeling in Cancer Cachexia as a Determinant of Checkpoint Inhibitor Efficacy and Toxicity.

The discovery of immune checkpoints links autoimmunity and cancer, with thymus atrophy reportedly causing autoimmune multiorgan inflammation. The impact of cancer cachexia on thymic involution and its clinical significance remains unclear. This study aimed to investigate this effect and its...

🗓️ 2025-08-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreThymic Microenvironment Remodeling in Cancer Cachexia as a Determinant of Checkpoint Inhibitor Efficacy and Toxicity.

High expression of the cachexia-related protein Fn14 in esophageal squamous cell carcinoma correlates with poor chemotherapy response and anti-Fn14 therapy decreases chemotherapeutic resistance.

In cancer cachexia, cytokine release by tumours causes weight loss, decreased therapeutic efficacy, and worsened prognosis. Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) and fibroblast inducible factor 14 (Fn14) are cancer cachexia-related proteins; however, their expression in oesophageal squamous...

🗓️ 2025-07-15
📰 Publication: British Journal Of Cancer
Read MoreHigh expression of the cachexia-related protein Fn14 in esophageal squamous cell carcinoma correlates with poor chemotherapy response and anti-Fn14 therapy decreases chemotherapeutic resistance.

GDF15: from biomarker to target in cancer cachexia.

Most patients with advanced cancer suffer from cachexia, a complex metabolic disorder characterized by unintentional body weight loss that diminishes their quality of life and reduces the effectiveness of therapies. Currently, effective treatments for cachexia remain elusive. Growth differentiation factor...

🗓️ 2025-07-09
📰 Publication: Trends In Cancer
Read MoreGDF15: from biomarker to target in cancer cachexia.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!